Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Very Weak
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Telephone
61.13.0043.6363
Address
D2 661 Newcastle Street Leederville, Western Australia (WA) 6007
Description
Emyria Ltd. is a healthcare technology and services company. It operates a network of specialist medical clinics and uses purpose-built software and technology to gather clinical data from informed and consenting patients. The company was founded on March 19, 2018 and is headquartered in Leederville, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.04 - 0.12
Trade Value (12mth)
AU$7,436.00
1 week
2.17%
1 month
14.63%
YTD
-14.55%
1 year
-58.83%
All time high
0.50
EPS 3 yr Growth
-41.800%
EBITDA Margin
-421.80%
Operating Cashflow
-$4m
Free Cash Flow Return
-55.40%
ROIC
-75.40%
Interest Coverage
-52.20
Quick Ratio
0.90
Shares on Issue (Fully Dilluted)
333m
HALO Sector
Technology
Next Company Report Date
27-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
19 July 24 |
Notice of General Meeting/Proxy Form
×
Notice of General Meeting/Proxy Form |
19 July 24 |
Letter to Shareholders - Notice of General Meeting
×
Letter to Shareholders - Notice of General Meeting |
15 July 24 |
Ceasing to be a substantial holder
×
Ceasing to be a substantial holder |
15 July 24 |
Becoming a substantial holder
×
Becoming a substantial holder |
01 July 24 |
Emyria, UWA Secure $499K Grant for MDMA Analogue Program
×
Emyria, UWA Secure $499K Grant for MDMA Analogue Program |
20 June 24 |
Empax Centre Selected As Key Site In Global PTSD Study
×
Empax Centre Selected As Key Site In Global PTSD Study |
11 June 24 |
Management Changes
×
Management Changes |
10 May 24 |
Change in substantial holding
×
Change in substantial holding |
07 May 24 |
Application for quotation of securities - EMD
×
Application for quotation of securities - EMD |
07 May 24 |
Notification regarding unquoted securities - EMD
×
Notification regarding unquoted securities - EMD |
07 May 24 |
Section 708A(5)(e) Notice
×
Section 708A(5)(e) Notice |
26 April 24 |
March 2024 Quarterly Activities Report and Appendix 4C
×
March 2024 Quarterly Activities Report and Appendix 4C |
23 April 24 |
Emyria Receives Bids of $2.3M to Expand Clinical Services
×
Emyria Receives Bids of $2.3M to Expand Clinical Services |
23 April 24 |
Proposed issue of securities - EMD
×
Proposed issue of securities - EMD |
19 April 24 |
Trading Halt
×
Trading Halt |
10 April 24 |
Emyria Opens Empax Centre to Advance Mental Health Care
×
Emyria Opens Empax Centre to Advance Mental Health Care |
05 April 24 |
Emyria Expands Specialist AP Team - First Female for MDMA-AT
×
Emyria Expands Specialist AP Team - First Female for MDMA-AT |
03 April 24 |
Emyria, Reach Wellness Enter MDMA-AT Research Agreement
×
Emyria, Reach Wellness Enter MDMA-AT Research Agreement |
19 March 24 |
Notification of cessation of securities - EMD
×
Notification of cessation of securities - EMD |
12 March 24 |
Response to ASX Aware Query
×
Response to ASX Aware Query |
08 March 24 |
Response to ASX Price Query
×
Response to ASX Price Query |
29 February 24 |
Emyria Half Year Results FY2024
×
Emyria Half Year Results FY2024 |
28 February 24 |
Appendix 4D and Half Year End Financial Report
×
Appendix 4D and Half Year End Financial Report |
23 February 24 |
Notification of cessation of securities - EMD
×
Notification of cessation of securities - EMD |
02 February 24 |
Webinar Presentation
×
Webinar Presentation |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.